Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
LSD
health economics
psilocybin
psychedelics
public health
sickness absence
sickness absenteeism
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
09 09 2022
09 09 2022
Historique:
received:
16
07
2022
revised:
05
09
2022
accepted:
06
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Absenteeism from work due to illness, and related costs, has increased steadily during the past decades. In recent years, there has been a reemergence of research on the therapeutic effects of classic psychedelics showing associations with both physical and mental health. However, the association between classic psychedelics and sick leave remains unknown. The aim of this study is to investigate the association between lifetime classic psychedelic use and sick leave in the past 30 days among adults in the United States ( The primary analysis was conducted using multiple linear regression, controlling for sociodemographic characteristics, risky behavior, and use of other substances. There was a significant and negative association between lifetime classic psychedelic use and sick leave in the past 30 days (B = -0.09, These findings suggest that classic psychedelics could potentially lead to reduced sick leave and associated costs in the general population, but more research is needed to investigate potential causal pathways of classic psychedelics on sick leave and evaluate possible mechanisms.
Identifiants
pubmed: 36141631
pii: ijerph191811353
doi: 10.3390/ijerph191811353
pmc: PMC9517576
pii:
doi:
Substances chimiques
Hallucinogens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA Psychiatry. 2021 May 1;78(5):481-489
pubmed: 33146667
J Psychoactive Drugs. 2020 Sep-Oct;52(4):289-299
pubmed: 32529966
Neuropharmacology. 2018 Nov;142:143-166
pubmed: 29753748
JAMA Psychiatry. 2021 Feb 1;78(2):121-122
pubmed: 32725172
Psychopharmacology (Berl). 2018 Feb;235(2):399-408
pubmed: 29119217
Expert Rev Clin Pharmacol. 2018 Sep;11(9):889-902
pubmed: 30102078
Lancet Psychiatry. 2016 Jul;3(7):619-27
pubmed: 27210031
J Psychopharmacol. 2015 Mar;29(3):289-99
pubmed: 25586396
Neuropharmacology. 2018 Nov;142:200-218
pubmed: 29284138
Scand J Prim Health Care. 2019 Mar;37(1):3-9
pubmed: 30689483
Soc Sci Med. 1992 May;34(9):1005-10
pubmed: 1631600
Scand J Public Health Suppl. 2004;63:49-108
pubmed: 15513654
Pharmacol Rev. 2016 Apr;68(2):264-355
pubmed: 26841800
J Psychopharmacol. 2019 Sep;33(9):1058-1067
pubmed: 30816808
Psychopharmacology (Berl). 2020 Apr;237(4):1161-1169
pubmed: 31927605
J Psychopharmacol. 2014 Nov;28(11):983-92
pubmed: 25213996
J Psychopharmacol. 2019 Sep;33(9):1088-1101
pubmed: 31084460
J Psychopharmacol. 2021 Apr;35(4):447-452
pubmed: 33719688
F1000Res. 2013 Mar 28;2:98
pubmed: 24627778
Psychol Med. 2020 Dec;50(16):2655-2666
pubmed: 33143790
Res Nurs Health. 2011 Dec;34(6):483-95
pubmed: 21953274
Neurosci Biobehav Rev. 2020 Jun;113:179-189
pubmed: 32194129
Med Hypotheses. 2020 Jan;134:109406
pubmed: 31634774
J Epidemiol Community Health. 2004 Apr;58(4):321-6
pubmed: 15026447
Lancet. 2010 Nov 6;376(9752):1558-65
pubmed: 21036393
JAMA Psychiatry. 2022 Aug 24;:
pubmed: 36001306
Int Rev Psychiatry. 2018 Aug;30(4):363-375
pubmed: 30102081
PLoS One. 2013 Aug 19;8(8):e63972
pubmed: 23976938
J Psychoactive Drugs. 2019 Apr-Jun;51(2):135-145
pubmed: 30732540
Front Pharmacol. 2016 Mar 02;7:35
pubmed: 26973523
Health Policy. 2006 Jun;77(1):51-63
pubmed: 16139925
J Psychopharmacol. 2022 Jan;36(1):12-19
pubmed: 34053342
Hypertension. 2021 May 5;77(5):1510-1516
pubmed: 33677982
Occup Med (Lond). 2018 Jun 20;68(5):320-326
pubmed: 29672758
BMC Public Health. 2019 May 3;19(1):500
pubmed: 31053139
Am J Med. 2016 Nov;129(11):1145-1148
pubmed: 27288855
Sci Rep. 2022 Apr 7;12(1):4099
pubmed: 35393455
J Psychopharmacol. 2017 May;31(5):606-613
pubmed: 28196428
Eur J Public Health. 2013 Aug;23(4):635-42
pubmed: 23302765
Sci Rep. 2021 Jul 13;11(1):14427
pubmed: 34257396
Eur J Health Econ. 2005 Dec;6(4):309-13
pubmed: 16133097
J Psychopharmacol. 2018 Jan;32(1):37-48
pubmed: 29039233
J Psychopharmacol. 2018 Jan;32(1):49-69
pubmed: 29020861